BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16270214)

  • 21. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers.
    Apostolova I; Ego K; Steffen IG; Buchert R; Wertzel H; Achenbach HJ; Riedel S; Schreiber J; Schultz M; Furth C; Derlin T; Amthauer H; Hofheinz F; Kalinski T
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2360-2373. PubMed ID: 27470327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
    Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.
    Dimitrakopoulou-Strauss A; Georgoulias V; Eisenhut M; Herth F; Koukouraki S; Mäcke HR; Haberkorn U; Strauss LG
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):823-30. PubMed ID: 16570185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer.
    Prévost S; Boucher L; Larivée P; Boileau R; Bénard F
    J Nucl Med; 2006 Apr; 47(4):559-65. PubMed ID: 16595487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
    J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
    Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
    Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography.
    Miles KA; Griffiths MR; Keith CJ
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):22-8. PubMed ID: 16180030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
    Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
    Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma.
    Guo J; Higashi K; Yokota H; Nagao Y; Ueda Y; Kodama Y; Oguchi M; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2004 Aug; 45(8):1334-9. PubMed ID: 15299058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.